LONDON, June 25 (Reuters) - U.S. regulators have deferred a decision on AstraZeneca’s (AZN.L) experimental infant lung drug motavizumab for two months, after outside advisers recommended against its approval in a panel review on June 2.
LONDON, June 25 (Reuters) - U.S. regulators have deferred a decision on AstraZeneca’s (AZN.L) experimental infant lung drug motavizumab for two months, after outside advisers recommended against its approval in a panel review on June 2.
